Clinical Trials Logo

Clinical Trial Summary

Peritoneal mesothelioma is a rare disease representing one third of all mesothelioma and nothing is known about molecular characteristics of this disease. As main cancers, genetic heterogeneity is probable. This genomic profiling associates Comparative Genomic Hybridization (CGH) array, BAP1 sequencing and gene expression in order to discover a biomarker that could be used in the treatment of this rare disease. Corresponding histopathological and immunohistochemical report as all clinical data are available. All data with be merged to underline a few genes of interest on which we will focus our next investigations. Depending of our preliminary results, BAP1 mutations are expected, as it was also described in pleural mesothelioma. Mutations in oncogenic drivers that could be targeted by specific therapy will be on particular interest in management of this rare disease with bad prognosis.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT02834234
Study type Observational
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date May 2013
Completion date January 2016

See also
  Status Clinical Trial Phase
Recruiting NCT06057935 - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Phase 2
Recruiting NCT02588131 - A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Phase 2
Active, not recruiting NCT02834169 - French National Registry of Rare Peritoneal Surface Malignancies N/A
Recruiting NCT04847063 - Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies Phase 1
Active, not recruiting NCT03867578 - Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma N/A
Completed NCT02040142 - Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Phase 2
Recruiting NCT01617382 - Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Completed NCT01160458 - Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Phase 2
Completed NCT05041062 - A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma Phase 2
Recruiting NCT05337735 - A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Phase 2
Terminated NCT03608618 - Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Phase 1
Recruiting NCT03875144 - Treatment of Malignant Peritoneal Mesothelioma (MESOTIP) Phase 2